Clinical Trial Update: The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients [Phase 2, Phase 3]

View source ↗

Summary

Xolair (omalizumab) has been studied in patients with mastocytosis, and the Phase 2 and Phase 3 trials have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mastocytosis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: University of Zurich | Conditions: Mastocytosis | Phase 2, Phase 3 | Status: COMPLETED